









Markets
/
Stocks
/
nasdaq-yi
/

111 Inc

7.395USD

-0.055-0.74%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

374.74MMarket Cap

LossP/E TTM



111 Inc

7.395

-0.055-0.74%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of 111 Inc

Currency: USD Updated: 2026-02-06

Key Insights

111 Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

111 Inc's Score

Industry at a Glance

Industry Ranking

119 / 159

Overall Ranking

399 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

111 Inc Highlights

StrengthsRisks

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.

Undervalued

The company’s latest PE is -18.29, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 13.01K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of 111 Inc is 6.40, ranking 145 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 426.05M, representing a year-over-year decrease of 88.17%, while its net profit experienced a year-over-year decrease of 89.23%.

Score

Industry at a Glance

Previous score

6.40

Change



Financials

5.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.91

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

111 Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of 111 Inc is 8.33, ranking 21 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -18.29, which is -99.37% below the recent high of -0.11 and -3.18% above the recent low of -18.88.

Score

Industry at a Glance

Previous score

8.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for 111 Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of 111 Inc is 7.42, ranking 56 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 11.48 and the support level at 3.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.45

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.390

Buy

RSI(14)

72.438

Buy

STOCH(KDJ)(9,3,3)

38.866

Neutral

ATR(14)

1.105

High Vlolatility

CCI(14)

66.957

Neutral

Williams %R

59.169

Sell

TRIX(12,20)

3.161

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

7.383

Buy

MA10

6.497

Buy

MA20

5.735

Buy

MA50

4.308

Buy

MA100

4.387

Buy

MA200

5.893

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of 111 Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 6.89%, representing a quarter-over-quarter increase of 529.90%. The largest institutional shareholder is James Simons, holding a total of 13.01K shares, representing 0.26% of shares outstanding, with 1.54% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

First Pharmacia International

434.53K

Susquehanna International Group, LLP

29.91K

+102.54%

Renaissance Technologies LLC

Star Investors

13.01K

Morgan Stanley & Co. LLC

5.14K

Geode Capital Management, L.L.C.

2.44K

UBS Financial Services, Inc.

1.45K

-76.32%

SBI Securities Co., Ltd.

184.00

-17.86%

J.P. Morgan Securities LLC

23.00

+187.50%

Parametric Portfolio Associates LLC

27.00

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 111 Inc is 2.72, ranking 121 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. 111 Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.